vs
CASTLE BIOSCIENCES INC（CSTL）与EXACT SCIENCES CORP（EXAS）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是CASTLE BIOSCIENCES INC的10.1倍（$878.4M vs $87.0M）。EXACT SCIENCES CORP同比增速更快（23.1% vs 0.8%）。EXACT SCIENCES CORP自由现金流更多（$120.4M vs $19.7M）。过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 9.2%）
Castle Biosciences是一家处于商业阶段的诊断企业，专注于开发和商业化针对黑色素瘤等皮肤癌及罕见病的专利临床诊断检测产品，主要服务美国医疗市场，聚焦未被满足的精准诊断需求领域，辅助临床医生制定治疗决策。
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
CSTL vs EXAS — 直观对比
营收规模更大
EXAS
是对方的10.1倍
$87.0M
营收增速更快
EXAS
高出22.3%
0.8%
自由现金流更多
EXAS
多$100.7M
$19.7M
两年增速更快
EXAS
近两年复合增速
9.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $87.0M | $878.4M |
| 净利润 | — | $-86.0M |
| 毛利率 | 79.0% | 70.1% |
| 营业利润率 | -4.4% | -9.4% |
| 净利率 | — | -9.8% |
| 营收同比 | 0.8% | 23.1% |
| 净利润同比 | — | 90.1% |
| 每股收益（稀释后） | $-0.06 | $-0.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSTLEXAS
| Q4 25 | $87.0M | $878.4M | ||
| Q3 25 | $83.0M | $850.7M | ||
| Q2 25 | $86.2M | $811.1M | ||
| Q1 25 | $88.0M | $706.8M | ||
| Q4 24 | $86.3M | $713.4M | ||
| Q3 24 | $85.8M | $708.7M | ||
| Q2 24 | $87.0M | $699.3M | ||
| Q1 24 | $73.0M | $637.5M |
净利润CSTLEXAS
| Q4 25 | — | $-86.0M | ||
| Q3 25 | $-501.0K | $-19.6M | ||
| Q2 25 | $4.5M | $-1.2M | ||
| Q1 25 | $-25.8M | $-101.2M | ||
| Q4 24 | — | $-864.6M | ||
| Q3 24 | $2.3M | $-38.2M | ||
| Q2 24 | $8.9M | $-15.8M | ||
| Q1 24 | $-2.5M | $-110.2M |
毛利率CSTLEXAS
| Q4 25 | 79.0% | 70.1% | ||
| Q3 25 | 77.5% | 68.6% | ||
| Q2 25 | 79.5% | 69.3% | ||
| Q1 25 | 81.4% | 70.8% | ||
| Q4 24 | 81.3% | 69.0% | ||
| Q3 24 | 81.8% | 69.4% | ||
| Q2 24 | 83.3% | 69.8% | ||
| Q1 24 | 81.0% | 70.0% |
营业利润率CSTLEXAS
| Q4 25 | -4.4% | -9.4% | ||
| Q3 25 | -8.2% | -3.0% | ||
| Q2 25 | -4.9% | -0.3% | ||
| Q1 25 | -31.7% | -13.6% | ||
| Q4 24 | 4.7% | -122.8% | ||
| Q3 24 | 5.9% | -5.6% | ||
| Q2 24 | 5.8% | -3.8% | ||
| Q1 24 | -7.5% | -16.7% |
净利率CSTLEXAS
| Q4 25 | — | -9.8% | ||
| Q3 25 | -0.6% | -2.3% | ||
| Q2 25 | 5.2% | -0.1% | ||
| Q1 25 | -29.4% | -14.3% | ||
| Q4 24 | — | -121.2% | ||
| Q3 24 | 2.6% | -5.4% | ||
| Q2 24 | 10.3% | -2.3% | ||
| Q1 24 | -3.5% | -17.3% |
每股收益（稀释后）CSTLEXAS
| Q4 25 | $-0.06 | $-0.45 | ||
| Q3 25 | $-0.02 | $-0.10 | ||
| Q2 25 | $0.15 | $-0.01 | ||
| Q1 25 | $-0.90 | $-0.54 | ||
| Q4 24 | $0.32 | $-4.69 | ||
| Q3 24 | $0.08 | $-0.21 | ||
| Q2 24 | $0.31 | $-0.09 | ||
| Q1 24 | $-0.09 | $-0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $299.5M | $964.7M |
| 总债务越低越好 | $10.1M | — |
| 股东权益账面价值 | $470.9M | $2.4B |
| 总资产 | $578.6M | $5.9B |
| 负债/权益比越低杠杆越低 | 0.02× | — |
8季度趋势，按日历期对齐
现金及短期投资CSTLEXAS
| Q4 25 | $299.5M | $964.7M | ||
| Q3 25 | $287.5M | $1.0B | ||
| Q2 25 | $275.9M | $858.4M | ||
| Q1 25 | $275.2M | $786.2M | ||
| Q4 24 | $293.1M | $1.0B | ||
| Q3 24 | $95.0M | $1.0B | ||
| Q2 24 | $85.6M | $946.8M | ||
| Q1 24 | $82.9M | $652.1M |
总债务CSTLEXAS
| Q4 25 | $10.1M | — | ||
| Q3 25 | $10.0M | — | ||
| Q2 25 | $10.0M | — | ||
| Q1 25 | $10.0M | — | ||
| Q4 24 | $10.0M | — | ||
| Q3 24 | $10.0M | — | ||
| Q2 24 | $10.0M | — | ||
| Q1 24 | $10.0M | — |
股东权益CSTLEXAS
| Q4 25 | $470.9M | $2.4B | ||
| Q3 25 | $467.0M | $2.5B | ||
| Q2 25 | $455.4M | $2.5B | ||
| Q1 25 | $440.3M | $2.4B | ||
| Q4 24 | $455.8M | $2.4B | ||
| Q3 24 | $441.1M | $3.2B | ||
| Q2 24 | $423.9M | $3.2B | ||
| Q1 24 | $402.5M | $3.1B |
总资产CSTLEXAS
| Q4 25 | $578.6M | $5.9B | ||
| Q3 25 | $562.8M | $5.9B | ||
| Q2 25 | $544.7M | $5.8B | ||
| Q1 25 | $501.7M | $5.7B | ||
| Q4 24 | $531.2M | $5.9B | ||
| Q3 24 | $514.6M | $6.7B | ||
| Q2 24 | $487.3M | $6.7B | ||
| Q1 24 | $458.5M | $6.4B |
负债/权益比CSTLEXAS
| Q4 25 | 0.02× | — | ||
| Q3 25 | 0.02× | — | ||
| Q2 25 | 0.02× | — | ||
| Q1 25 | 0.02× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | 0.02× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $26.9M | $151.7M |
| 自由现金流经营现金流 - 资本支出 | $19.7M | $120.4M |
| 自由现金流率自由现金流/营收 | 22.7% | 13.7% |
| 资本支出强度资本支出/营收 | 8.3% | 3.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $28.3M | $356.8M |
8季度趋势，按日历期对齐
经营现金流CSTLEXAS
| Q4 25 | $26.9M | $151.7M | ||
| Q3 25 | $22.6M | $219.9M | ||
| Q2 25 | $20.8M | $89.0M | ||
| Q1 25 | $-6.0M | $30.8M | ||
| Q4 24 | $24.4M | $47.1M | ||
| Q3 24 | $23.3M | $138.7M | ||
| Q2 24 | $24.0M | $107.1M | ||
| Q1 24 | $-6.8M | $-82.3M |
自由现金流CSTLEXAS
| Q4 25 | $19.7M | $120.4M | ||
| Q3 25 | $7.8M | $190.0M | ||
| Q2 25 | $11.6M | $46.7M | ||
| Q1 25 | $-10.8M | $-365.0K | ||
| Q4 24 | $16.8M | $10.7M | ||
| Q3 24 | $17.0M | $112.6M | ||
| Q2 24 | $18.8M | $71.2M | ||
| Q1 24 | $-16.0M | $-120.0M |
自由现金流率CSTLEXAS
| Q4 25 | 22.7% | 13.7% | ||
| Q3 25 | 9.4% | 22.3% | ||
| Q2 25 | 13.4% | 5.8% | ||
| Q1 25 | -12.2% | -0.1% | ||
| Q4 24 | 19.5% | 1.5% | ||
| Q3 24 | 19.8% | 15.9% | ||
| Q2 24 | 21.6% | 10.2% | ||
| Q1 24 | -21.9% | -18.8% |
资本支出强度CSTLEXAS
| Q4 25 | 8.3% | 3.6% | ||
| Q3 25 | 17.9% | 3.5% | ||
| Q2 25 | 10.7% | 5.2% | ||
| Q1 25 | 5.4% | 4.4% | ||
| Q4 24 | 8.8% | 5.1% | ||
| Q3 24 | 7.4% | 3.7% | ||
| Q2 24 | 6.0% | 5.1% | ||
| Q1 24 | 12.5% | 5.9% |
现金转化率CSTLEXAS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.60× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.29× | — | ||
| Q2 24 | 2.69× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSTL
| Dermatologic | $48.6M | 56% |
| Non Dermatologic | $38.4M | 44% |
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
